Antonio Cigliola
YOU?
Author Swipe
View article: Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study Open
Although it is an uncommon and not standard strategy, previous ICI in nonmetastatic UC and a period of ≥12 months after previous ICI in the metastatic setting were associated with better outcomes after ICI rechallenge in patients with aUC.
View article: The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis Open
ICI+TKI combinations increase the risk of MACEs compared to controls, although the absolute incidence is eventually low. Routine cardiovascular monitoring in asymptomatic patients is therefore not recommended.
View article: Use of 18F‐fluoro‐2‐deoxy‐ <scp>d</scp> ‐glucose <scp>(18F‐FDG) PET</scp> / <scp>CT</scp> for lymph node assessment before radical cystectomy in bladder cancer patients
Use of 18F‐fluoro‐2‐deoxy‐ <span>d</span> ‐glucose <span>(18F‐FDG) PET</span> / <span>CT</span> for lymph node assessment before radical cystectomy in bladder cancer patients Open
Objective To assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) f…
View article: Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer
Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer Open
Objective To evaluate the predictive capability of the pre‐ and post‐pembrolizumab Vesical Imaging–Reporting and Data System (VI‐RADS) to identify ypT0N0 or ypT≤1N0 response in muscle‐invasive bladder cancer (MIBC) within the PURE‐01 trial…
View article: Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy Open
In this study, the addition of BRIs to abiraterone acetate with prednisone as first-line therapy for the treatment of patients with mCRPC and bone metastases was associated with longer OS, particularly in patients with high-volume disease.…